Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The poor survival of Veterans with oral cancer underscores the significance of identifying
new treatment approaches. The proposed studies will test a new 2 pronged immunotherapeutic
approach for oral cancer patients which lessen the immune inhibitory environment while
maturing cells that can stimulate T cell reactivity against oral cancer cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
VA Office of Research and Development
Treatments:
Calcitriol Celecoxib Dihydroxycholecalciferols Vitamin D